NCT04946890View on ClinicalTrials.gov

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Acute Myeloid Leukemia Leukemia
Interventions
DRUG

MRX2843

MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively

Trial Locations (1)

200025

Junmin Li，Ph.D, Shanghai

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04946890 - A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter